Page last updated: 2024-10-28

lidocaine and Cognition Disorders

lidocaine has been researched along with Cognition Disorders in 12 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.

Research Excerpts

ExcerptRelevanceReference
"Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels."5.27Confusion and paranoia associated with oral tocainide. ( Clarke, CW; el-Mahdi, EO, 1985)
"The lidocaine group had lower serum MDA levels than those in the control group."2.80Neuroprotective effects of intravenous lidocaine on early postoperative cognitive dysfunction in elderly patients following spine surgery. ( Chen, K; Li, J; Wei, P; Zheng, Q; Zhou, J, 2015)
"Lidocaine was not neuroprotective."2.74Cerebral protection by lidocaine during cardiac operations: a follow-up study. ( Davies, E; Frampton, C; Gorman, DF; Grieve, D; Merry, AF; Mills, BP; Milsom, FP; Mitchell, SJ; Webster, CS; Willcox, TW, 2009)
"Isoflurane may not cause long-lasting neuropathological changes."1.38Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats. ( Cao, L; Li, J; Lin, D; Wang, Z; Washington, JM; Zuo, Z, 2012)
"Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels."1.27Confusion and paranoia associated with oral tocainide. ( Clarke, CW; el-Mahdi, EO, 1985)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19902 (16.67)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Hung, KC1
Ho, CN1
Liu, WC1
Yew, M1
Chang, YJ1
Lin, YT1
Hung, IY1
Chen, JY1
Huang, PW1
Sun, CK1
Habibi, MR2
Habibi, V2
Habibi, A1
Soleimani, A1
Chen, K1
Wei, P1
Zheng, Q1
Zhou, J1
Li, J3
Peng, Y1
Zhang, W1
Zhou, X1
Ji, Y1
Kass, IS1
Han, R1
Gholipour Baradari, A1
Nouraei, SM1
Mathew, JP1
Mackensen, GB1
Phillips-Bute, B1
Grocott, HP1
Glower, DD1
Laskowitz, DT1
Blumenthal, JA1
Newman, MF1
Mitchell, SJ1
Merry, AF1
Frampton, C1
Davies, E1
Grieve, D1
Mills, BP1
Webster, CS1
Milsom, FP1
Willcox, TW1
Gorman, DF1
Lin, D1
Cao, L1
Wang, Z1
Washington, JM1
Zuo, Z1
Butterworth, J1
Hammon, JW1
Wang, D1
Wu, X1
Xiao, F1
Liu, X1
Meng, M1
Schneck, DW1
Clarke, CW1
el-Mahdi, EO1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
S100B Protein as Predictor of Cognitive Dysfunction After Robot-assisted Radical Prostatectomy: A Prospective Observational Study[NCT03018522]89 participants (Actual)Observational2017-02-14Completed
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
Continuous Cerebral Autoregulation Monitoring to Reduce Brain Injury From Cardiac Surgery[NCT00981474]460 participants (Actual)Interventional2009-09-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Acute Kidney Injury Within 7 Days After Surgery.

Subject developed acute kidney injury within 7 days after surgical procedure. Based on Kidney disease: Improving Global Outcomes (KDIGO) classification system. (NCT00981474)
Timeframe: 7 days after surgery

InterventionParticipants (Count of Participants)
Control56
Intervention62

Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery.

The composite neurological outcome was composed of clinical stroke, or new ischemic lesions detected on postoperative brain diffusion weighted magnetic resonance imaging(DWI), or cognitive decline from baseline to 4-6 weeks after surgery. (NCT00981474)
Timeframe: Up to 6 weeks post-operative

InterventionParticipants (Count of Participants)
Usual Care Group (Control)79
Autoregulation Group70

Insertion of Intra-aortic Balloon Pump

Procedural insertion of intra-aortic balloon pump within 7 days after surgical procedure (NCT00981474)
Timeframe: 7 days after surgery

InterventionParticipants (Count of Participants)
Control19
Intervention14

Mechanical Lung Ventilation>24 Hours After Surgery

Subjects need for mechanical lung ventilation more than 24 hours after planned surgical procedure. (NCT00981474)
Timeframe: Up to 28 days after surgery.

InterventionParticipants (Count of Participants)
Control22
Intervention13

Mortality

Subject death within 28 days after surgical procedure (NCT00981474)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Control12
Intervention5

Multiple Inotropic Drugs>24 Hours After Surgery

Use of multiple inotropic drugs greater than 24 hours after the planned surgical procedure until discharge from the hospital. (NCT00981474)
Timeframe: 7 days after surgery

Interventionparticipants (Number)
Usual Care Group (Control)13
Autoregulation Group6

Multisystem Organ Failure After Surgery

Subject diagnosis of multisystem organ failure after surgery. (NCT00981474)
Timeframe: Up to 28 days after surgery.

InterventionParticipants (Count of Participants)
Control7
Intervention2

New Renal Replacement Therapy

Subjects requiring new renal replacement therapy prior to discharge from hospital (NCT00981474)
Timeframe: Up to 28 days after surgery.

InterventionParticipants (Count of Participants)
Control6
Intervention4

Postoperative Atrial Fibrillation

Clinical diagnosis of postoperative atrial fibrillation from date of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.

InterventionParticipants (Count of Participants)
Control89
Intervention79

Postoperative Delirium

Assessed with Confusion Assessment Method or Confusion Assessment Method-ICU along with adjudication by team of experts (NCT00981474)
Timeframe: Postoperative days 1-4

InterventionParticipants (Count of Participants)
Usual Care Group (Control)34
Autoregulation Group19

Sepsis

Clinical diagnosis of sepsis from time of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.

InterventionParticipants (Count of Participants)
Control7
Intervention2

Reviews

3 reviews available for lidocaine and Cognition Disorders

ArticleYear
Prophylactic effect of intravenous lidocaine against cognitive deficit after cardiac surgery: A PRISMA-compliant meta-analysis and trial sequential analysis.
    Medicine, 2022, Sep-02, Volume: 101, Issue:35

    Topics: Adult; Anesthetics, Local; Cardiac Surgical Procedures; Cognition; Cognition Disorders; Humans; Lido

2022
Lidocaine dose-response effect on postoperative cognitive deficit: meta-analysis and meta-regression.
    Expert review of clinical pharmacology, 2018, Volume: 11, Issue:4

    Topics: Cognition Disorders; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Lidocaine; Ne

2018
Administration of lidocaine to prevent cognitive deficit in patients undergoing coronary artery bypass grafting and valve plasty: a systematic review and meta-analysis.
    Expert review of clinical pharmacology, 2017, Volume: 10, Issue:2

    Topics: Cardiac Valve Annuloplasty; Cognition Disorders; Coronary Artery Bypass; Humans; Lidocaine; Voltage-

2017

Trials

5 trials available for lidocaine and Cognition Disorders

ArticleYear
Neuroprotective effects of intravenous lidocaine on early postoperative cognitive dysfunction in elderly patients following spine surgery.
    Medical science monitor : international medical journal of experimental and clinical research, 2015, May-15, Volume: 21

    Topics: Aged; Aged, 80 and over; Anesthesia, General; Cognition Disorders; Female; Humans; Infusions, Intrav

2015
Lidocaine Did Not Reduce Neuropsychological-Cognitive Decline in Patients 6 Months After Supratentorial Tumor Surgery: A Randomized, Controlled Trial.
    Journal of neurosurgical anesthesiology, 2016, Volume: 28, Issue:1

    Topics: Adult; Anesthetics, Local; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Lido

2016
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
    Stroke, 2009, Volume: 40, Issue:3

    Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind

2009
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
    Stroke, 2009, Volume: 40, Issue:3

    Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind

2009
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
    Stroke, 2009, Volume: 40, Issue:3

    Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind

2009
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
    Stroke, 2009, Volume: 40, Issue:3

    Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind

2009
Cerebral protection by lidocaine during cardiac operations: a follow-up study.
    The Annals of thoracic surgery, 2009, Volume: 87, Issue:3

    Topics: Brain Diseases; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind Method; Female; Follo

2009
The effect of lidocaine on early postoperative cognitive dysfunction after coronary artery bypass surgery.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:5

    Topics: Aged; Anesthesia; Anesthetics, Local; Cardiopulmonary Bypass; Cognition Disorders; Coronary Artery B

2002

Other Studies

4 other studies available for lidocaine and Cognition Disorders

ArticleYear
Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats.
    Behavioural brain research, 2012, Mar-17, Volume: 228, Issue:2

    Topics: Aging; Amyloid beta-Peptides; Anesthetics, Inhalation; Anesthetics, Local; Animals; Brain; Cognition

2012
Lidocaine for neuroprotection: more evidence of efficacy.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:5

    Topics: Cardiac Surgical Procedures; Cognition Disorders; Humans; Lidocaine; Neuroprotective Agents; Neurops

2002
Therapeutic rounds at the Milton S. Hershey Medical Center: central nervous system toxicity caused by lidocaine.
    Clinical therapeutics, 1983, Volume: 5, Issue:6

    Topics: Cognition Disorders; Confusion; Drug Interactions; Heart Failure; Humans; Lidocaine; Male; Middle Ag

1983
Confusion and paranoia associated with oral tocainide.
    Postgraduate medical journal, 1985, Volume: 61, Issue:711

    Topics: Administration, Oral; Cognition Disorders; Confusion; Female; Humans; Lidocaine; Middle Aged; Parano

1985